Review
Open access
The 2025 KSPNO Guideline for the Diagnosis and Treatment of Medulloblastoma
Nalee Kim
Jaeho Cho
Tae-Young Jung
Sung-Hye Park
S. Nam
Y. Cha
Y. S. Lee
Youngkyong Kim
D. Lim
H. Yoon
J. Lee
S. Chung
Boram Ha
Kyung-Nam Koh
J. Lee
J. Choi
Jung-Woo Han
Jae Min Lee
Y. Choi
K. Shim
J. Phi
J. Choi
S. Chong
Ju-Seong Kim
Jeyul Yang
Jun Kyu Hwang
Ye-On J. Lim
J. Suh
Jung-Eun Cheon
Ah-Young Jung
J. Kim
Y. Shim
Hee Jo Baek
Miyoung Choi
Hyeon Jin Park
Se Hoon Kim
Medicine
Abstract
Medulloblastoma is the most common malignant pediatric brain tumor. While recent advances in molecular subclassification and therapies have improved clinical outcomes, standardized international treatment guidelines are currently lacking. In this context, the Korean Society for Pediatric Neuro-Oncology (KSPNO) developed the 2025 National Cancer Treatment Guideline through a multidisciplinary task force, employing rigorous PICO-based literature reviews and evidence grading (e.g., ROB 2.0, GRADE). This framework aims to standardize diagnosis, staging, and treatment (surgery, chemotherapy, and radiotherapy) to promote evidence-based care in Korea.